Quotes 5-day view Delayed Nasdaq
01/15/2021
01/19/2021
01/20/2021
01/21/2021
01/22/2021
Date
517.93(c)
533.89(c)
542.27(c)
535.48(c)
540.79 Last
796 883
995 530
862 666
940 229
137 755 Volume
0.00% +3.08% +1.57% -1.25% +0.99% Change
Sales 2020
8 545 M - -
Net income 2020
3 178 M - -
Net cash position 2020
5 478 M - -
P/E ratio 2020
19,1x
Yield 2020
-
Sales 2021
10 573 M - -
Net income 2021
3 772 M - -
Net cash position 2021
9 418 M - -
P/E ratio 2021
14,6x
Yield 2021
-
Capitalization
56 517 M 56 517 M -
EV / Sales 2020
5,97x
EV / Sales 2021
4,45x
Nbr of Employees
8 314
Free-Float
83,1%
Regeneron Pharmaceuticals specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Sales break down by activity as follows:
- sales of products (61.5%);
- supply of collaborative services (33.3%): working with Sanofi (54.5% of sales) and Bayer (45.5%);
- sales of technology licenses (5.2%). The group also provides subcontracting...
Notations Surperformance© of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
All news about REGENERON PHARMACEUTICALS
News in other languages on REGENERON PHARMACEUTICALS
Analyst Recommendations on REGENERON PHARMACEUTICALS
U.S. hospitals to restrict Lilly COVID-19 antibody treatment due to limited supply
Chart REGENERON PHARMACEUTICALS
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends REGENERON PHARMACEUTICALS
Short Term Mid-Term Long Term Trends Bullish Bearish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
27
Average target price
654,96 $
Last Close Price
535,48 $
Spread / Highest target
48,1%
Spread / Average Target
22,3%
Spread / Lowest Target
-6,63%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
